AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01908660
Drug: antiretroviral drugs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: zidovudine lamivudine emtricitabine abacavir tenofovir nevirapine efavirenz etravirine rilpivirine lopinavir atazanavir fosamprenavir darunavir raltegravir maraviroc ritonavir
Trial: NCT03090568
Drug: BIA 5-453
RxNorm normalized name: Oatmeal 10 mg in 1 mL TOPICAL CREAM [BIA Eczema Relief]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BIA 5-453 capsules 50 mg. Route of administration: Oral. In one period subjects received 4 capsules of 50 mg of BIA 5-453 after a fasting of at least 10 hours, and in the other period subjects were dosed with 4 capsules of 50 mg of BIA 5-453 after a standard high-fat and high-calorie meal
Trial: NCT01414153
Drug: 4.0 mg iSONEP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4.0 mg iSONEP given monthly intravitreously for 4 months
Trial: NCT00533442
Drug: Steroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Part of standard maintenance
Trial: NCT01539590
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily intravenous administration for four (4) days. The volume of normal saline will vary by estimated weight.
Trial: NCT01414153
Drug: 0.5 mg iSONEP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg iSONEP given monthly intravitreously for 4 months
Trial: NCT01414153
Drug: 0.5 mg Lucentis or 1.25 mg Avastin or 2 mg Eylea
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg Lucentis or 1.25 mg Avastin or 2 mg Eylea given monthly intravitreously for 4 months
Trial: NCT00156312
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT04062045
Drug: Saline 0.9%
RxNorm normalized name: CVS Saline 0.9% Nasal Mist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group B will receive Saline 0,9% through the erector spinae catheter.
Trial: NCT01545856
Drug: levodopa
RxNorm normalized name: Levodopa
DrugBank: Levodopa (DB01235)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: levodopa use
Trial: NCT02807987
Drug: CS-3150
RxNorm normalized name: MyoGesic-CS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CS-3150 1.25 to 2.5, 5mg, orally
Trial: NCT01967550
Drug: diclofenac diethylamine, DDEA 2.32% gel
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01967550
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01117220
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matching the oral ziprasidone capsules of 20,40, 60 and 80 mg in strength. Subjects will be dosed for 4 weeks using a flexible dose design with minimal dose range of 40 mg twice a day (BID) to maximum dose range of 80 mg BID (weight specific- \< 45kg max dose 40 mg BID).
Trial: NCT03212937
Drug: ICE Chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV Ifosfamide 5g/m\^2 on Day 2 (inpatient) or D1 (outpatient) of each 21-day cycle~IV Carboplatin AUC 5 on Day 2 (inpatient) or D1-3 (outpatient) of each 21-day cycle~IV Etoposide 100 mg/m\^2 on Days 1-3 of each 21-day cycle
Trial: NCT02255422
Drug: Placebo capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02072811
Drug: Consolidation, I HAM cycle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * Ara-C 3g/m2; 3h infusion iv every 12h on 1,2,3 days~* Mitoxantrone 10mg/m2; 0,5h infusion iv on 3,4,5 days
Trial: NCT03826550
Drug: Diclofenac Sodium Gel
RxNorm normalized name: diclofenac sodium Topical Gel
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Twice daily for 60 days. Each patient is expected to receive 120 doses
Trial: NCT03826550
Drug: Solaraze 3% Topical Gel
RxNorm normalized name: Solaraze 3% Topical Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice daily for 60 days. Each patient is expected to receive 120 doses
Trial: NCT01343004
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 0 mcg subcutaneous daily
Trial: NCT01343004
Drug: BA058 80 mcg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BA058 80 mcg subcutaneous daily
Trial: NCT00313794
Drug: CP-675,206
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg/kg IV q 3 months for 4 cycles in the absence of disease progression or unacceptable toxicity.
Trial: NCT03725553
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: the group received a 10-mL bolus injection of saline into the myometrium during slow (30-seconds)as soon as the umbilical cord was clamped.
Trial: NCT00176995
Drug: 15% Eflornithine Hdyrochloride
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04408586
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo looks exactly like the study drug, but it contains no active ingredient
Trial: NCT01989897
Drug: diluent, saline with HSA--phenol
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01634594
Drug: Group R
RxNorm normalized name: Typhus group rickettsia Ab
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01730638
Drug: • TF2 and 68 Ga-IMP-288
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03306030
Drug: Three times dose of 4L PEG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The same as mentioned above. The participants began to drink the first 1.5 L of PEG at 2:00 PM and the second 1.5L of PEG at 8:00PM on the day before colonoscopy at a rate of 250 mL every 15 minutes. On the day of the procedure, patients take the remaining 1.0 L 4-6 hours before colonoscopy.
Trial: NCT01634594
Drug: Group D
RxNorm normalized name: Prostaglandin group D
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02257151
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03307577
Drug: UHE-101 Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical cream containing investigational drug at a concentration of 1%
Trial: NCT00460733
Drug: Calcium & Vitamine D3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg of calcium and 400 UI of Vitamine D3
Trial: NCT01874561
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (commercially available normal saline) will be administered iv using an infusion pump over a 2-hour period.
Trial: NCT00005613
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide will be given at a dose of 1500 mg/m2/day IV over 1.0 hour on days -6, -5, -4, and -3.
Trial: NCT00088374
Drug: [15-O] H2O
FDA approved: no
EMA approved: no
PMDA approved: no
Description: \[15-0\] H20 performed at baseline and 12 weeks after treatment. At each time point participants can receive 250mCi 0-15 water and 15 mCi F18-FDG. The water scans were done as several intravenous injections for several scans but not over a total of 250 mCi.
Trial: NCT01440621
Drug: Pyridoxine
RxNorm normalized name: PYRIDOXINE
DrugBank: Pyridoxine phosphate (DB02209)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tablet Pyridoxine 10mg once a day at 8AM daily, from Day one of RT till first post-treatment followup. Tab Pyridoxine 10mg has been chosen as placebo as it resembles Tab Modafinil 100mg in physical appearance, size and shape. Tab Pyridoxine is unlikely to affect Cancer Related Fatigue on its own as all patients on RT are already on multivitamin supplements as per our institutional guidelines.
Trial: NCT00661115
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo. After a 4 week run-in period, subjects were randomized in order to enroll 3 times more subjects in the vardenafil group than in the placebo group. The duration of the active treatment phase was 12 weeks
Trial: NCT03535688
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: twice daily
Trial: NCT02177357
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01595997
Drug: DLX105
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intradermal injections (volume: 0.1 mL) of 0.02 mg (low dose cohort), 1 mg (high dose cohort) DLX105, days: Day 1, Day 4, Day 7 and Day 10
Trial: NCT01594983
Drug: LCQ908
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00414102
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ramelteon placebo-matching tablets, orally, once nightly for up to 28 days.
Trial: NCT00127907
Drug: epinephrine (1 mg/1 mL)
RxNorm normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03670953
Drug: IR CD-LD
RxNorm normalized name: IR-3535
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active comparator - IR CD-LD
Trial: NCT03670953
Drug: IPX203 ER CD-LD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Investigational formulation - ER CD-LD
Trial: NCT01594983
Drug: Placebo of LCQ908
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo of LCQ908
Trial: NCT02665845
Drug: Corticosteroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroids will be given to all patients.
Trial: NCT02227693
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matching 20-mg tablets
Trial: NCT01934569
Drug: Pravastatin, midazolam, losartan, omeprazole, caffeine and PF-05089771
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PF-05089771 450mg single dose and titration from 150mg BID to 450mg BID Pravastatin 10mg dingle dose, Midazolam 7.5mg single dose, Losartan 25mg single dose, Caffeine 100mg single dose, Omeprazole 20mg single dose
Trial: NCT03718507
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: atropine (0.01-0.02 mg/kg i.v. bolus) and fentanyl (0.5-2 mcg/kg i.v. in 5 minutes)
Trial: NCT00216411
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03522441
Drug: Clindamycin 1% Gel
RxNorm normalized name: BENZOYL PRX 5%/CLINDAMYCIN 1% GEL KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical gel
Trial: NCT03522441
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical Placebo gel
Trial: NCT04148261
Drug: Hydrocortisone Acetate (CORT)
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Participants will receive a single dose of hydrocortisone at a dosage of 0.65 mg/kg
Trial: NCT04148261
Drug: Epinephrine Sulfate (EPI)
RxNorm normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will receive a continuous infusion of epinephrine at a dosage of 80 ng/kg/min
Trial: NCT01661140
Drug: Methotrexate (stable dose)
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate (MTX) was administered weekly according to the subject's pre-study MTX dose
Trial: NCT01661140
Drug: Methotrexate (tapering dose)
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Tapering doses of methotrexate (MTX) were administered weekly from Week 24 to Week 56. Tapering doses depended on dose administered to the subject during the open label period. First tapering occurred at randomization (Week 24), second tapering at Week 32, third tapering at Week 40 and final tapering at Week 48.
Trial: NCT04667351
Drug: 2400 mg/m² 5-fu
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hepatic arterial infusion of oxaliplatin,leucovorin and 2400 mg/m² 5-FU
Trial: NCT04667351
Drug: 1200 mg/m² 5-fu
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hepatic arterial infusion of oxaliplatin,leucovorin and 1200 mg/m² 5-FU
Trial: NCT00838396
Drug: Placebo for XP19986 CR
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02103569
Drug: FDC of Norethindrone and Ethinyl Estradiol
RxNorm normalized name: ethinyl estradiol / norethindrone
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02646072
Drug: Ketorolac tromethamine ophthalmic solution 0.45%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indicated for the treatment of pain and inflammation following cataract surgery.
Trial: NCT02170116
Drug: Placebo to BIBR 1048 MS
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02736032
Drug: External Estradiol
RxNorm normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Estradiol started on day1 of the cycle for endometrial prepartaion
Trial: NCT02509091
Drug: Bronchoalveolar Lavage and Local Amikacin Injection
RxNorm normalized name: Amikacin
DrugBank: Amikacin (DB00479)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: injecting 0.4g of AK in 100 ml to 250 ml, not exceeding 300 ml. And generally, repeat it for 3 to 5 times.
Trial: NCT00777972
Drug: Fosinopril sodium and hydrochlorothiazide 20-12.5 mg tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT05396742
Drug: rHuPH20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution for infusion
Trial: NCT03547622
Drug: MAT taper with placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Following taper from MAT (methadone or buprenorphine) participants will be given placebo daily with access to a CBT4CBT computer program
Trial: NCT02028715
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline (100cc) will be given IV as the placebo medication every six hours for a total of eight doses with the first dose being given at time of anesthesia induction.
Trial: NCT02028715
Drug: IV acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV acetaminophen (1,000mg) will be given every six hours for a total of eight doses with the first dose being given at time of anesthesia induction.
Trial: NCT02561845
Drug: rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5mg, 10mg, 20mg
Trial: NCT01324232
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo capsules administered once daily for first 7 days followed by twice daily for 11 weeks of the study to complete 12 weeks of treatment.
Trial: NCT02301975
Drug: Placebo inhalation powders via ELLIPTA inhaler
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo inhalation powders administered once daily via ELLIPTA inhaler. 30 doses per device.
Trial: NCT02301975
Drug: Placebo inhalation powder via ACCUHALER/DISKUS inhaler
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo inhalation powder administered twice daily via ACCUHALER/DISKUS inhaler. 60 doses per device.
Trial: NCT03509350
Drug: Thiamine
RxNorm normalized name: Thiamine
DrugBank: Thiamine (DB00152)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous thiamine (100 mg every 6 hours) will be administered for 4 days or until ICU discharge.
Trial: NCT03509350
Drug: Hydrocortisone
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Intravenous hydrocortisone (50 mg every 6 hours) will be administered for 4 days or until ICU discharge.
Trial: NCT03509350
Drug: Vitamin C Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A placebo to match intravenous vitamin C (1.5 grams every 6 hours) will be administered for 4 days or until ICU discharge.
Trial: NCT03509350
Drug: Thiamine Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A placebo to match intravenous thiamine (100 mg every 6 hours) will be administered for 4 days or until ICU discharge.
Trial: NCT03509350
Drug: Hydrocortisone Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A placebo to match intravenous hydrocortisone (50 mg every 6 hours) will be administered for 4 days or until ICU discharge. Steroids will be used when clinically indicated.
Trial: NCT02927522
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, 1 pill/ day for 7 days Po, was administrated from the day before surgery.
Trial: NCT02585011
Drug: Epinephrine
RxNorm normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01357486
Drug: Pravastatin
RxNorm normalized name: Pravastatin
DrugBank: Pravastatin (DB00175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: patients receiving pravastatin 40 mg - once a day
Trial: NCT01357486
Drug: Sorafenib + Pravastatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: patients receiving sorafenib 400 mg (twice a day) and pravastatin 40 mg (once a day)
Trial: NCT00896311
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV injection, initial dose of 1ml, with further doses of 1-3mL, up to a recommended maximum of 10mL
Trial: NCT01137591
Drug: APAP and NAC combination
RxNorm normalized name: acetaminophen / codeine phosphate Oral Suspension [Capital and Codeine]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: APAP 650mg and NAC 600mg combination oral tablet administered once
Trial: NCT01137591
Drug: APAP and Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: APAP 650mg and Placebo combination oral tablet administered once
Trial: NCT04030091
Drug: 2 hours humulin R 100 IU/mL PIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: As described for the Intervention 3 hours of pulsatile insulin infusion (PIT) with humulin R 100 IU/mL, the treatment duration is just one hour less.
Trial: NCT03086460
Drug: Placebo pMDI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matched Placebo
Trial: NCT01987765
Drug: Relestat Ophthalmic Solution 0.05%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Relestat Ophthalmic Solution 0.05% prescribed as local standard of care in clinical practice.
Trial: NCT02905331
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive matching placebo supplied in a PFS assembled in a SelfDose device.
Trial: NCT01002950
Drug: ACU-4429
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACU-4429 tablets (2, 5, 7, or 10 mg) taken orally once daily for 90 days
Trial: NCT01002950
Drug: Matching placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo tablets taken orally once daily for 90 days
Trial: NCT00927095
Drug: Continuous OC (EE/DROS)
RxNorm normalized name: OC 8 Adult Acne
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous EE(20ug)+DROS(3mg) daily for 3 months
Trial: NCT00927095
Drug: Intermittent OC (EE/DROS)
RxNorm normalized name: OC 8 Adult Acne
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent EE(20ug)+DROS(3mg) daily for 21 days each month
Trial: NCT00927095
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: daily placebo
Trial: NCT04087525
Drug: HIP1701
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vildagliptin
Trial: NCT04087525
Drug: HGP1809
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vildagliptin
Trial: NCT02905565
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Take 4 capsules BID on an empty stomach at least 1 hour before food intake, and remain fasting at least 1 hour after dosing
Trial: NCT00868283
Drug: 0.9% Saline Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 ml will be given once daily by intravenous infusion for 10 consecutive days.
Trial: NCT00006112
Drug: chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00006112
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00006112
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT04196868
Drug: Methotrexate treatment
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: per os
Trial: NCT00772603
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-active tablet identical to study drug tablets
Trial: NCT00772603
Drug: 2400mg SPN-804
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tablets containing 600mg OXC XR, identical to non-active tablets
Trial: NCT00772603
Drug: 1200mg SPN-804
FDA approved: no
EMA approved: no
PMDA approved: no
Description: two active tablets and two non-active tablets, all identical
Trial: NCT00996684
Drug: Placebo control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo control will be the microplasmin vehicle without the microplasmin.
Trial: NCT00776607
Drug: Tablet treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Step 1: Lifestyle modification. If HbA1c at 7%+ or if on metformin/sulphonylurea go to step 2. Step 2: Glucophage. If HbA1c of 7%-7.5% give 500mg x 1 per day. If HbA1c 7.6%-8.0%, week 1 - 500mg x 1 day and then 500mg x 2 day. If HbA1c 8.0%+ then 500mg x 3 per day (Titrated). If HbA1c remains 7%+ give additional tablet until 2gms per day then progress to Step 3. Step 3: Rosiglitazone. HbA1c of 7%+ give 4 mg per day. If HbA1c remains 7%+ titrate to maximal dose 4 mg twice daily +/-Metformin. If HbA1c remains 7% + for an 3 months move to step 4. Before initiation of Rosiglitazone repeat medical history with special emphasis on cardiovascular disease, if patient has a history of CVD move to Step 4 (insulin). Any adverse events suggestive of heart disease move to step 4. Step 4: Insulin (oral agents will be stopped). Initiation of insulin will the same as for the insulin arm and will follow the protocol detailed in the Insulin arm.
Trial: NCT01607918
Drug: D1-D5: (lansoprazole + amoxicillin ) D6-D10: (lansoprazole+clarithromycin +metronidazole)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D1-D5: (lansoprazole 30mg + amoxicillin 1gm) bid D6-D10: (lansoprazole 30mg+clarithromycin 500mg+metronidazole 500mg) bid
Trial: NCT01607918
Drug: D1-D14: (lansoprazole + clarithromycin + amoxicillin)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D1-D14: (lansoprazole 30mg + clarithromycin 500mg + amoxicillin 1gm) bid